H uman septic shock is a complex syndrome displaying a high degree of heterogeneity (1-3). Our inability to manage and account for this heterogeneity is a major barrier to the conduct of more effective clinical trials. Multiple interventional clinical trials have been attempted in human septic shock and the majority of these trials have failed to demonstrate efficacy despite being founded on quality preclinical data and sound biological principles. It has been proposed that these repeated failures reflect our relative inability to address the profound heterogeneity of septic shock, rather than intrinsic flaws of the biological principles being tested (1, 4) . Robust illness severity scores are currently available for critically ill pediatric and adult populations, but it is clear that these scores are not appropriate tools to stratify individual patients for the purposes of clinical trials (5, 6) . Thus, there remains a need to develop more effective, clinical stratification/staging strategies for septic shock to meet the needs of clinical research and individual patient management. Successful achievement of this goal holds the promise of improving our therapeutic approach to human septic shock in an analogous manner to what has been achieved in the oncology field (7) (8) (9) (10) (11) .
We (12) recently reported the identification of three subclasses of children with septic shock as a means to address more effectively the intrinsic heterogeneity of this syndrome. The three subclasses were initially identified based exclusively on genome-wide expression patterns, using microarray analysis and unsupervised hierarchical clustering. Importantly, the gene expression patterns represented the first 24 hrs of meeting criteria for septic shock, which is an ideal time frame for clinically relevant stratification. Post hoc phenotype analyses revealed that patients in one of the three subclasses had significantly higher illness severity, organ failure rates, and mortality, compared with the other two subclasses, thus indicating that the expression-based subclasses are clinically relevant (12) . We further refined our subclassification strategy to a 100-gene signature. Herein we report our initial attempt to develop a "clinicianfriendly" stratification strategy based on these 100 class-predictor genes and the use of gene expression "mosaics."
METHODS
Patients and Microarray Analysis. The 98 patients in the septic shock study cohort and their respective microarray studies have been previously reported with detailed clinical data and confirmation of Institutional Review Board approval (12) . We conducted genomewide expression studies, using the Human Genome U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA) and whole blood-derived ribonucleic acid from 98 individual children meeting published criteria for septic shock (13) (14) (15) (16) . All microarray data used in the current report represent the first 24 hrs of meeting the criteria for septic shock. Using discovery-oriented expression/statistical gene filters and unsupervised hierarchical clustering techniques, we identified three subclasses of children with septic shock based exclusively on their respective genome-wide expression patterns (heretofore referred to as "subclass A," "subclass B," and "subclass C"). Subclass A patients had significantly higher illness severity, organ failure rates, and mortality, compared with subclass B and C patients (12) . Using K-means clustering and class prediction modeling, we refined the class-defining signature to 100 genes (Supplementary Data for the 100 gene probe list). The microarrayderived expression patterns of these 100 classdefining genes are the basis of the current report.
Generation of Gene Expression Mosaics. Expression mosaics representing the 100 classdefining genes were generated, using the Gene Expression Dynamics Inspector (GEDI) platform. GEDI is a publicly available gene expression analysis program developed by the Ingber Laboratory at Harvard University (17, 18) . The signature graphical outputs of GEDI are gene expression mosaics that give microarray data a "face" that is intuitively recognizable via human pattern recognition (19 -22) . The underlying algorithm for creating the mosaics is a selforganizing map. Conventional applications of self-organizing maps involve classifying genes or samples into predetermined numbers of discrete clusters. In contrast, GEDI creates an selforganizing map-based mosaic for every sample. Thus, GEDI is said to be "sample oriented" rather than "gene oriented." Extensive technical details regarding GEDI can be found at http://www.childrenshospital.org/research/ingber/ GEDI/gedihome.htm.
Data Analysis. The individual patients' microarray expression data for the 100 classdefining genes were uploaded to the GEDI platform, and individual gene expression mosaics were generated for each patient. Subsequently, we generated composite mosaics for each of the three subclasses. The respective composite mosaics represent the average expression patterns of the individual patients within a given subclass.
We next conducted internal cross validation procedures to test the ability of the GEDI mosaics to accurately identify the three subclasses of children with septic shock. Nine individual clinicians participated as evaluators in the cross validation procedures. The nine evaluators are all practicing pediatric critical care medicine specialists. Only one of the nine evaluators has experience interpreting microarray data. Each evaluator was shown the 98 individual patient mosaics, and each evaluator was asked to classify each patient as subclass "A," "B," or "C," based on the individual expression patterns/mosaics and using the composite mosaics as the reference point. The individual evaluators were not provided with any additional prompting or instructions and were blinded to the original patient subclassifications.
Individual evaluator responses were catalogued to determine the ability of the individual mosaics to accurately subclassify patients based on the originally published subclassifications. When discrepancies occurred for a given patient (i.e., different evaluators classified a given patient into more than one class), the "majority vote" (i.e., Ն5 votes for a given class) was considered as the final/consensus Figure 1 as the reference point.
classification for that given patient. For example, if six of the evaluators classified an individual patient as "subclass B," and the other three evaluators classified the same patient as "subclass C," then that patient was assigned to subclass B (i.e., the consensus classification). The performance characteristics of the classification strategy (i.e., specificity, sensitivity) and 95% confidence intervals were based on the consensus classifications of the nine individual evaluators. We also calculated performance characteristics for each individual evaluator. Performance characteristics were calculated, using a Web-based clinical calculator (http://faculty.vassar.edu/lowry/clin1.html) and the originally published subclassifications as the gold standard. To further measure interrater/evaluator agreement across the nine evaluators, a coefficient for multiple evaluators was calculated, using a Web-based calculator (http://cosmion.net/jeroen/software/ kappa/).
RESULTS
The composite mosaics for the three septic shock subclasses are shown in Figure 1 . Examples of individual patient mosaics are provided in Figure 2 . There was 100% concordance across the nine evaluators for 62 (63%) of the 98 patients. That is, for 63% of the patients, all nine evaluators classified them to the same subclass. More specifically, there was 100% concordance across the nine evaluators for 82% of patients in subclass A, 69% of patients in subclass B, and 32% of patients in subclass C. For 80% of the patients in the entire cohort, at least eight of the nine evaluators classified them to the same subclass. The average coefficient across all possible interrater/ evaluator comparisons was 0.81 (0 ϭ no agreement; 1 ϭ perfect agreement).
The performance characteristics of the subclassification strategy, based on consensus classification, are provided in Table 1. Twenty-seven (96%) of the 28 original subclass A patients were correctly classified as subclass A. Thirty-eight (84%) of the 45 original subclass B patients were correctly classified as subclass B. Twenty-three (92%) of the 25 original subclass C patients were correctly classified as subclass C. The respective sensitivities, specificities, positive predictive values, and negative predictive values of the subclassification strategy were Ն84% across the three subclasses. In addition, the subclassification strategy yielded positive likelihood ratios of Ն16.8 and negative likelihood ratios of Յ0.2 across the three subclasses. Table 1 also provides the number of patients incorrectly classified. Two original subclass B and two original subclass C patients were incorrectly classified as subclass A patients. Figure 3 provides the individual mosaics for these incorrectly classified patients. Four original subclass B patients were incorrectly classified as subclass C patients. Figure 4 provides the individual mosaics for these incorrectly classified patients. No patient was incorrectly classified as subclass B. All of the incorrectly classified patients were survivors.
There were two patients who did not receive at least five "votes" (i.e., the majority vote) for any of the three subclasses and, therefore, remained unclassified. Figure 5 provides the individual mosaics for these two patients. The patient represented by example 1 was an original subclass A patient but received three votes for each of the subclasses. The patient represented by example 2 was an original subclass B patient but received three votes for subclass A, four votes for subclass B, and two votes for subclass C. Both of these unclassified patients were survivors.
The performance characteristics for each one of the nine individual evaluators are provided in Table 2 . In addition, the median and intraquartile performance characteristics of the nine individual evaluators are provided in Table 3 . These data demonstrate similar performance characteristics between the consensus classifications and the individual evaluator classifications.
DISCUSSION
We have provided initial evidence for a clinically feasible and robust stratification strategy for children with septic shock. The assertion of feasibility is supported at two levels. First, the stratification strategy is based on a 100 gene signature, using whole blood-derived ribonucleic acid. With current multiplex technology (e.g., quantitative polymerase chain reaction or digital quantification of messenger ribonucleic acid abundance) and a dedicated molecular diagnostics laboratory, it is now feasible to quantify the expression levels of 100 genes within a timeframe that is clinically acceptable (23) . Second, the subclassification strategy relies on intuitive pattern recognition of GEDI-generated gene expression mosaics. We have demonstrated that clinicians without formal training in bioinformatics and complex gene expression analysis can interpret accurately these mosaics in a relatively reproducible and reliable manner, as objectively measured by a statistic. We would expect that, with additional training and experience in the interpretation of these mosaics, correct response rates could be improved further.
The assertion of robustness is also supported at two levels. First, the data used for subclassification represent the first 24 hrs of meeting the criteria for septic shock in the pediatric intensive care unit. This time frame is ideal for the goals of patient stratification and identifies a subclass of children (i.e., subclass A patients) having a substantially higher illness severity and mortality (36% mortality vs. 11% mortality) than the other two subclasses, with sensitivity and specificity of Ն94% (12) . The ability to reliably stratify patients within this timeframe could allow for the more selective enrollment of patients into clinical trials and for the selection of individual patients for currently available high-risk therapies (e.g., extracorporeal membrane oxygenation). In the case of clinical trial stratification, the strategy is potentially most useful when the test intervention carries more than minimal risk. For example, patients with a low risk of mortality, who otherwise meet the clinical entry criteria, could potentially be excluded and thereby not be exposed to the risks of the test agent. Alternatively, patients with a high risk of mortality could be selected more reliably for enrollment. In either case, the net result of this type of approach would be to optimize the risk to benefit the ratio of a given experimental therapy.
Second, the performance characteristics of the stratification strategy demonstrate the ability to reliably classify patients into the correct categories with a high level of sensitivity and specificity, and high positive and negative predictive values. In addition, the positive and negative likelihood ratios are well above or below cutoffs, respectively, that are considered to be clinically relevant (24) .
This initial proof-of-concept study has important limitations from the standpoint of validation. We have not prospectively validated the existence of these three subclasses with regard to the expression patterns and the related clinical phenotypes. Our original study that led to the identification of the three putative classes was conducted in a rigorous manner, but has not yet been prospectively validated in an independent cohort of patients. Accordingly, the veracity of these subclasses, while biologically plausible, remains to be formally demonstrated. Related to this limitation, the current study was conducted, using an internal crossvalidation approach based on the same patients as the original study. This 100 gene-and mosaic-based approach also requires formal prospective validation in a separate cohort of patients.
These limitations notwithstanding, we have taken an important first step in bringing genomic-based data closer to the bedside of critically ill children for the purpose of clinically relevant stratifi- cation: proof-of-concept. A major barrier to the application of genomic data in the field of critical care medicine has been the translation, interpretation, and acceptance of these complex data by clinicians. We propose that the mosaic-based strategy described in this report may potentially allow for the use of genomic data by clinicians at the bedside of critically ill children. Validation studies to directly test this proposal are currently in progress.
